NY-ESO-1 (157-165) C165V - SLLMWITQV – General analogue epitope of tumor cells

 

HLA-A*02 Major Histocompatibility Complex (MHC) allele

 

HLA-A*02 allele is expressed in class I Human MHC Leukocyte Antigens (HLA),that are cell surface receptors,presenting peptides to the immune system. If a non-self-peptide is recognized by cytotoxic T-cells in the blood,cell death will be initiated via apoptosis.

 

NY-ESO-1 protein

 

Peptides presented by MHC class I molecule,are usually between 7 and 11 amino acids,originating from proteins expressed by the cell. SLLMWITQV peptide differes from the New York esophageal squamous cell carcinoma 1 (NY-ESO-1 : UniProt - P78358) native SLLMWITQC peptide,whose protein is part of a well-characterized group of cancer/testis antigens (CTAs).

Normally,NY-ESO-1 expression is restricted to germ cells and placental cells. However it is also expressed in 82% of neuroblastomas and 46% of melanomas,as well as in many other solid tumors and hematological malignancies.

 

NY-ESO-1 (157-165) C165V peptide application

 

Class I HLA molecules of the cancerous cells cited above present peptides from NY-ESO-1 protein,including SLLMWITQC,that binds the binding cleft of the HLA-A*0201 complex. NY-ESO-1 being the most immunogenic among the CTA family members,its peptides constitute attractive targets for specific immunotherapies and the stimulation of human NY-ESO-1 specific CD8+ T cells.

In order to better stimulate specific cytotoxic T-cells in PBMCs and analyze by ELISPOT peptide epitope,specificity,and cytokine production,like IFN-γ,SLLMWITQV variant peptide was used,as it is known to have a higher affinity for the binding cleft of the HLA-A*0201 complex than the native peptide. Moreover,SLLMWITQV has been used with adjuvant in protein nanoparticles in order to study cell-mediated immune responses and is also used in clinical trial to study the immunological effects of vaccines containing NY-ESO-1 (157-165) C165V.

SB-PEPTIDE also offers NY-ESO-1 (157-165) native peptide,as well as NY-ESO-1 (157-165) C165V biotinylated and scrambled versions.

 

Technical specifications

 NY-ESO-1 (157-165) Sequence : SLLMWITQV
 NY-ESO-1 (157-165) peptide synthesis MW : 1090 ,34 g/mol (C51H83N11O13S)
 NY-ESO-1 (157-165) price Purity : > 95%
Peptide Library synthesis Counter-Ion : TFA Salts (see option TFA removal)
Peptide library synthesis NY-ESO-1 (157-165) Delivery format : Freeze dried in propylene 2mL microtubes
peptide solubility guidelines Peptide Solubility Guideline
buy peptide price Bulk peptide quantities available

 

Price

Product catalog Size Price € HT Price $ HT
SB062-1MG 1 mg 88 110
SB062-5MG 5 mg 308 385
SB062-10MG 10 mg 522 653
SB062-50MG 50 mg 1815 2268

 

References

For Bulk Orders